JP2018502922A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502922A5 JP2018502922A5 JP2017555422A JP2017555422A JP2018502922A5 JP 2018502922 A5 JP2018502922 A5 JP 2018502922A5 JP 2017555422 A JP2017555422 A JP 2017555422A JP 2017555422 A JP2017555422 A JP 2017555422A JP 2018502922 A5 JP2018502922 A5 JP 2018502922A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- ebola virus
- vector
- virus antigen
- adenovirus type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 21
- 241001115402 Ebolavirus Species 0.000 claims 16
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 241001135569 Human adenovirus 5 Species 0.000 claims 10
- 108090000288 Glycoproteins Proteins 0.000 claims 8
- 102000003886 Glycoproteins Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 102100021592 Interleukin-7 Human genes 0.000 claims 5
- 108010002586 Interleukin-7 Proteins 0.000 claims 5
- 230000002163 immunogen Effects 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 230000002950 deficient Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 230000008088 immune pathway Effects 0.000 claims 3
- 230000010076 replication Effects 0.000 claims 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 241000884921 Bundibugyo ebolavirus Species 0.000 claims 2
- 102100038078 CD276 antigen Human genes 0.000 claims 2
- -1 CD86 Proteins 0.000 claims 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 2
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 241001115394 Reston ebolavirus Species 0.000 claims 2
- 241001115376 Sudan ebolavirus Species 0.000 claims 2
- 230000024932 T cell mediated immunity Effects 0.000 claims 2
- 241001115374 Tai Forest ebolavirus Species 0.000 claims 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 2
- 101150010086 VP24 gene Proteins 0.000 claims 2
- 101150026858 VP30 gene Proteins 0.000 claims 2
- 101150077651 VP35 gene Proteins 0.000 claims 2
- 101150036892 VP40 gene Proteins 0.000 claims 2
- 241001115400 Zaire ebolavirus Species 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 230000008350 antigen-specific antibody response Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims 1
- 101150029662 E1 gene Proteins 0.000 claims 1
- 101150005585 E3 gene Proteins 0.000 claims 1
- 101150066038 E4 gene Proteins 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 102100031351 Galectin-9 Human genes 0.000 claims 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 102100034980 ICOS ligand Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 102000003810 Interleukin-18 Human genes 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102000000646 Interleukin-3 Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 102000004473 OX40 Ligand Human genes 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 101710188053 Protein D Proteins 0.000 claims 1
- 101710132893 Resolvase Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101968P | 2015-01-09 | 2015-01-09 | |
| US62/101,968 | 2015-01-09 | ||
| PCT/US2016/012482 WO2016112188A1 (en) | 2015-01-09 | 2016-01-07 | Methods and compositions for ebola virus vaccination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018502922A JP2018502922A (ja) | 2018-02-01 |
| JP2018502922A5 true JP2018502922A5 (enExample) | 2019-02-14 |
Family
ID=56356425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555422A Pending JP2018502922A (ja) | 2015-01-09 | 2016-01-07 | エボラウイルスワクチン接種のための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10695417B2 (enExample) |
| EP (1) | EP3256140B1 (enExample) |
| JP (1) | JP2018502922A (enExample) |
| KR (1) | KR20170102002A (enExample) |
| CN (1) | CN107530383A (enExample) |
| AU (1) | AU2016205208A1 (enExample) |
| CA (1) | CA2973109A1 (enExample) |
| ES (1) | ES2795833T3 (enExample) |
| WO (1) | WO2016112188A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009006479A2 (en) | 2007-07-02 | 2009-01-08 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
| KR20170102002A (ko) | 2015-01-09 | 2017-09-06 | 이투빅스 코포레이션 | 에볼라 바이러스 백신접종을 위한 방법 및 조성물 |
| CN109803677A (zh) | 2016-07-15 | 2019-05-24 | 埃特彼塞斯公司 | 用于α病毒疫苗接种的组合物和方法 |
| EP3484509A4 (en) * | 2016-07-15 | 2020-03-25 | Etubics Corporation | COMPOSITIONS AND METHODS FOR VACCINATION AGAINST FLAVIVIRUS |
| WO2018039640A1 (en) * | 2016-08-26 | 2018-03-01 | The Broad Institute, Inc. | Nucleic acid amplification assays for detection of pathogens |
| US12622961B2 (en) | 2019-09-10 | 2026-05-12 | The Penn State Research Foundation | Lipopolysaccharide molecules for enhancing immune responses |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| US20210284716A1 (en) * | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| WO2021183665A1 (en) * | 2020-03-11 | 2021-09-16 | Nant Holdings Ip, Llc | Treatment of covid-19 and methods therefor |
| EP4118109A1 (en) | 2020-03-11 | 2023-01-18 | NantCell, Inc. | Proteinaceous therapeutics |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| EP4377336A4 (en) | 2021-07-29 | 2025-07-16 | Nantcell Inc | MODIFIED T CELL RECEPTORS FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS AND CANCER |
| EP4335870A1 (en) | 2022-09-06 | 2024-03-13 | NantCell, Inc. | Peptide therapeutics against sars-cov-2 spike protein |
| WO2024228950A1 (en) * | 2023-05-04 | 2024-11-07 | Immunitybio, Inc. | Adenoviral vector transduced apheresis product |
| WO2025238195A1 (en) * | 2024-05-16 | 2025-11-20 | Ferring International Center S.A. | Method for the purification of recombinant adenovirus vectors |
| US20260001951A1 (en) | 2024-06-28 | 2026-01-01 | Immunitybio, Inc. | Anti-SLAMF7 Antibodies And Therapeutics |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US6045802A (en) | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US7118754B1 (en) | 1996-07-30 | 2006-10-10 | Transgene S.A. | Pharmaceutical composition for treating papillomavirus tumors and infection |
| US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
| US6716823B1 (en) | 1997-08-13 | 2004-04-06 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| US6706693B1 (en) | 1997-08-13 | 2004-03-16 | The Uab Research Foundation | Vaccination by topical application of genetic vectors |
| US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
| ATE421888T1 (de) | 1997-08-13 | 2009-02-15 | Uab Research Foundation | Impfung durch topische verwendung genetischer vektoren |
| US6756038B1 (en) | 1997-10-10 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
| EP1447414B1 (en) | 1997-10-10 | 2007-06-06 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Antagonist peptides of carcinoembryonic antigen (CEA) |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| PT1447414E (pt) | 1997-10-10 | 2007-07-18 | Us Gov Health & Human Serv | Péptidos antagonistas do antigénio carcinoembrionário ( cea ). |
| US6413513B1 (en) | 1998-05-22 | 2002-07-02 | Entremed, Inc. | Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
| US6734172B2 (en) | 1998-11-18 | 2004-05-11 | Pacific Northwest Research Institute | Surface receptor antigen vaccines |
| JP4409097B2 (ja) | 1998-12-09 | 2010-02-03 | アメリカ合衆国 | 複数の共刺激分子を発現する組換えベクターおよびその利用 |
| US20040009936A1 (en) | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
| US7001995B1 (en) | 1999-08-25 | 2006-02-21 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
| AU1013601A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
| AU2001280674A1 (en) | 2000-07-20 | 2002-02-05 | Genstar Therapeutics Corporation | Mini-adenoviral vector system for vaccination |
| AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| US20040091995A1 (en) | 2001-06-15 | 2004-05-13 | Jeffrey Schlom | Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
| WO2003008649A1 (en) | 2001-07-20 | 2003-01-30 | Board Of Regents, The University Of Texas System | Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin |
| ATE369895T1 (de) | 2002-04-09 | 2007-09-15 | Sanofi Pasteur Ltd | Modifizierte cea nucleinsäure und expressionsvektoren |
| US8236776B2 (en) | 2002-04-09 | 2012-08-07 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
| JP2006515318A (ja) | 2002-10-29 | 2006-05-25 | ファルマシア・コーポレーション | 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法 |
| CN1548537B (zh) | 2002-12-27 | 2010-05-05 | 深圳市源兴生物医药科技有限公司 | 疫苗制备方法和抗肿瘤疫苗 |
| US20070104685A1 (en) | 2003-05-05 | 2007-05-10 | Nicola La Monica | Synthetic gene encoding human carcinoembryonic antigen and uses thereof |
| US8207314B2 (en) | 2003-05-16 | 2012-06-26 | Sanofi Pasteur Limited | Tumor antigens for prevention and/or treatment of cancer |
| CN100558894C (zh) | 2003-07-21 | 2009-11-11 | P.安杰莱蒂分子生物学研究所 | 编码人表皮生长因子2/neu抗原的合成基因及其用途 |
| WO2005051991A2 (en) | 2003-11-24 | 2005-06-09 | Sidney Kimmel Cancer Center | Mucin antigen vaccine |
| WO2005058950A2 (en) | 2003-12-11 | 2005-06-30 | Sidney Kimmel Cancer Center | Methods for generating immunity to antigen |
| AU2004299457B2 (en) | 2003-12-12 | 2011-03-24 | Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services | A human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1 |
| ES2387850T3 (es) | 2004-02-11 | 2012-10-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | Proteína de fusión al antígeno carcinoembrionario y sus usos |
| EP1742657B1 (en) * | 2004-04-28 | 2013-11-06 | The Trustees of The University of Pennsylvania | Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost |
| KR101131727B1 (ko) | 2004-06-11 | 2012-03-28 | 가톨릭대학교 산학협력단 | ＣＥＡ-특이적인 세포독성 Ｔ세포를 생성하는 재조합 아데노바이러스 ＡｄＶＣＥＡ로 트랜스덕션된 수지상세포, 이를 포함하는 백신 및 약제학적 조성물 |
| EP2460533A3 (en) | 2004-10-18 | 2014-01-08 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| US20100034840A1 (en) | 2005-07-11 | 2010-02-11 | David Apelian | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| KR20140029551A (ko) | 2006-02-02 | 2014-03-10 | 글로브이뮨 | 면역 반응 유도를 위한 효모-기반 백신 |
| CN101426810A (zh) | 2006-04-21 | 2009-05-06 | 特朗斯吉恩股份有限公司 | 基于hpv-18的乳头瘤病毒疫苗 |
| WO2009006479A2 (en) | 2007-07-02 | 2009-01-08 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
| US8728489B2 (en) | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
| WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
| EP3320915A1 (en) | 2009-04-17 | 2018-05-16 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
| US20150182621A1 (en) | 2009-04-28 | 2015-07-02 | The Johns Hopkins University | Compositions and methods for enhancing antigen-specific immune responses |
| AU2010291985B2 (en) | 2009-09-14 | 2016-05-05 | The Regents Of The University Of Colorado | Modulation of yeast-based immunotherapy products and responses |
| WO2011115914A1 (en) | 2010-03-14 | 2011-09-22 | Globeimmune, Inc. | Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy |
| JP6096111B2 (ja) | 2010-05-10 | 2017-03-15 | アセンド・バイオファーマシューティカルズ・リミテッド | 免疫刺激組成物及びワクチン組成物 |
| WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
| WO2012106490A1 (en) * | 2011-02-03 | 2012-08-09 | The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Multivalent vaccines for rabies virus and filoviruses |
| JP5745102B2 (ja) | 2011-02-12 | 2015-07-08 | グローブイミューン，インコーポレイテッド | 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 |
| WO2012174220A1 (en) | 2011-06-14 | 2012-12-20 | Globeimmune, Inc. | Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection |
| RU2642300C2 (ru) | 2011-08-17 | 2018-01-24 | Глоубиммьюн, Инк. | Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения |
| US11155599B2 (en) | 2012-02-02 | 2021-10-26 | Board Of Regents, The University Of Texas System | Adenoviruses expressing heterologous tumor-associated antigens |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| ES2752190T3 (es) | 2012-09-14 | 2020-04-03 | Us Health | Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso |
| TWI626948B (zh) | 2013-03-26 | 2018-06-21 | 環球免疫公司 | 治療或預防人類免疫缺乏病毒感染之組合物及方法 |
| WO2015031778A2 (en) | 2013-08-30 | 2015-03-05 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of tuberculosis |
| US10350275B2 (en) * | 2013-09-21 | 2019-07-16 | Advantagene, Inc. | Methods of cytotoxic gene therapy to treat tumors |
| AU2014340201B2 (en) | 2013-10-23 | 2019-02-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use |
| CA3156357A1 (en) | 2014-01-06 | 2015-07-09 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| WO2015127027A1 (en) | 2014-02-20 | 2015-08-27 | Wayne State University | Her2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas |
| US10799567B2 (en) | 2014-04-11 | 2020-10-13 | Globeimmune, Inc. | Yeast-based immunotherapy and type I interferon sensitivity |
| KR102503476B1 (ko) | 2014-06-30 | 2023-02-24 | 알토 바이오사이언스 코포레이션 | Il-15-베이즈드 분자 및 이의 사용 방법 |
| WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| KR20170102002A (ko) | 2015-01-09 | 2017-09-06 | 이투빅스 코포레이션 | 에볼라 바이러스 백신접종을 위한 방법 및 조성물 |
| AU2016205215B2 (en) | 2015-01-09 | 2021-03-11 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| US11149087B2 (en) | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
-
2016
- 2016-01-07 KR KR1020177022208A patent/KR20170102002A/ko not_active Ceased
- 2016-01-07 JP JP2017555422A patent/JP2018502922A/ja active Pending
- 2016-01-07 EP EP16735409.1A patent/EP3256140B1/en active Active
- 2016-01-07 US US15/542,003 patent/US10695417B2/en active Active
- 2016-01-07 AU AU2016205208A patent/AU2016205208A1/en not_active Abandoned
- 2016-01-07 ES ES16735409T patent/ES2795833T3/es active Active
- 2016-01-07 WO PCT/US2016/012482 patent/WO2016112188A1/en not_active Ceased
- 2016-01-07 CN CN201680014847.2A patent/CN107530383A/zh active Pending
- 2016-01-07 CA CA2973109A patent/CA2973109A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508567A5 (enExample) | ||
| JP2019176869A5 (enExample) | ||
| Dyck et al. | Immune checkpoints and their inhibition in cancer and infectious diseases | |
| Bertram et al. | A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo | |
| AU2020357502B2 (en) | HBV vaccines and methods treating HBV | |
| Welsh et al. | Immunological memory to viral infections | |
| Bachmann et al. | Recall proliferation potential of memory CD8+ T cells and antiviral protection | |
| Condotta et al. | The immune battlefield: The impact of inflammatory cytokines on CD8+ T-cell immunity | |
| Marzi et al. | Ebola virus vaccines: an overview of current approaches | |
| Bosio et al. | Ebola and Marburg virus-like particles activate human myeloid dendritic cells | |
| JP2019508044A5 (enExample) | ||
| CN113260368A (zh) | 抗gpc3嵌合抗原受体(car)与反式共刺激分子的组合及其治疗用途 | |
| Willoughby et al. | Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization | |
| Buonaguro et al. | Immunogenomics and systems biology of vaccines | |
| Butler et al. | Immunologic considerations for generating memory CD8 T cells through vaccination | |
| JP2012515548A5 (enExample) | ||
| US11931408B2 (en) | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy | |
| Helmstetter et al. | Individual T helper cells have a quantitative cytokine memory | |
| JP2020514378A5 (enExample) | ||
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| Mahalingam et al. | The viral manipulation of the host cellular and immune environments to enhance propagation and survival: a focus on RNA viruses | |
| Frasca et al. | Aging, cytomegalovirus (CMV) and influenza vaccine responses | |
| JP2019521704A5 (enExample) | ||
| López-Medina et al. | Salmonella impairs CD8 T cell response through PD-1: PD-L axis | |
| Circelli et al. | Immunological effects of a novel RNA-based adjuvant in liver cancer patients |